In February, Ember’s (ex-Dyson) new CEO Jim Rowan described to TechCrunch the company’s plans to expand beyond the temperature-controlled smart mugs that bear his name. At the time, the executive cited the cold chain – especially drug transportation – as a potentially important category for the startup, going forward.
It looks like Ember is now ready to keep that promise, thanks to a new $ 23.5 million Series E that brings his total funding to around $ 70 million. Tellingly, the cycle was led by Foxconn subsidiary GOLDTek, as well as Singapore-based EDBI. The latter comes as Ember announces his intention to open an R&D center in the Southeast Asian country, with the aim of expanding his international presence.
This comes with an additional workforce for the company, which says it has already grown its team by 76% this year.
“Since launching Ember five years ago, our company’s mission has always been to use our expertise in precision temperature control to solve our customers’ real problems,” said the group’s founder and CEO. Clay Alexander in a statement. “To date, Ember has over 129 issued patents relating to temperature control, data and connectivity. This additional capital will be instrumental in bringing the technology in our extensive patent portfolio to life in the years to come, particularly in the area of infant health and nutrition. “
On the cold chain front, the company hinted at the upcoming arrival of its “first cloud-based self-refrigerated shipping box”. Targeting the pharmaceutical industry, the technology seeks to target a global supply chain currently under unprecedented pressure.